questionsmedicales.fr
Facteurs biologiques
Antigènes
Antigènes de surface
Molécules d'adhérence cellulaire
Lectine-2 de type Ig liant l'acide sialique
Lectine-2 de type Ig liant l'acide sialique : Questions médicales fréquentes
Termes MeSH sélectionnés :
Early Detection of Cancer
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Lectine-2 de type Ig liant l'acide sialique : Questions médicales les plus fréquentes",
"headline": "Lectine-2 de type Ig liant l'acide sialique : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Lectine-2 de type Ig liant l'acide sialique : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-26",
"dateModified": "2025-02-20",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Lectine-2 de type Ig liant l'acide sialique"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Molécules d'adhérence cellulaire",
"url": "https://questionsmedicales.fr/mesh/D015815",
"about": {
"@type": "MedicalCondition",
"name": "Molécules d'adhérence cellulaire",
"code": {
"@type": "MedicalCode",
"code": "D015815",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.050.301.350"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Lectine-2 de type Ig liant l'acide sialique",
"alternateName": "Sialic Acid Binding Ig-like Lectin 2",
"code": {
"@type": "MedicalCode",
"code": "D051918",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Ken Kitajima",
"url": "https://questionsmedicales.fr/author/Ken%20Kitajima",
"affiliation": {
"@type": "Organization",
"name": "Biocience and Biotechnology Center, Nagoya University, Nagoya, 464-8601, Japan."
}
},
{
"@type": "Person",
"name": "Chihiro Sato",
"url": "https://questionsmedicales.fr/author/Chihiro%20Sato",
"affiliation": {
"@type": "Organization",
"name": "Biocience and Biotechnology Center, Nagoya University, Nagoya, 464-8601, Japan. chi@agr.nagoya-u.ac.jp."
}
},
{
"@type": "Person",
"name": "Thomas Haselhorst",
"url": "https://questionsmedicales.fr/author/Thomas%20Haselhorst",
"affiliation": {
"@type": "Organization",
"name": "Institute for Glycomics, Griffith University, Gold Coast, Queensland, Australia."
}
},
{
"@type": "Person",
"name": "Dinglong Yang",
"url": "https://questionsmedicales.fr/author/Dinglong%20Yang",
"affiliation": {
"@type": "Organization",
"name": "Muping Coastal Environment Research Station, Yantai Institute of Coastal Zone Research, Chinese Academy of Sciences, Yantai, 264003, PR China; Center for Ocean Mega-science, Chinese Academy of Sciences, Qingdao, Shandong, 266071, PR China. Electronic address: dlyang@yic.ac.cn."
}
},
{
"@type": "Person",
"name": "Takeo Tatsuta",
"url": "https://questionsmedicales.fr/author/Takeo%20Tatsuta",
"affiliation": {
"@type": "Organization",
"name": "Division of Cell Recognition Study, Institute of Molecular Biomembrane and Glycobiology, Tohoku Medical and Pharmaceutical University."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Modelled mortality benefits of multi-cancer early detection screening in England.",
"datePublished": "2023-04-25",
"url": "https://questionsmedicales.fr/article/37185463",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41416-023-02243-9"
}
},
{
"@type": "ScholarlyArticle",
"name": "Impact of early detection on cancer curability: A modified Delphi panel study.",
"datePublished": "2022-12-21",
"url": "https://questionsmedicales.fr/article/36542647",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1371/journal.pone.0279227"
}
},
{
"@type": "ScholarlyArticle",
"name": "Advances in microRNAs as Emerging Biomarkers for Colorectal Cancer Early Detection and Diagnosis.",
"datePublished": "2024-10-15",
"url": "https://questionsmedicales.fr/article/39456841",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijms252011060"
}
},
{
"@type": "ScholarlyArticle",
"name": "REPRESENT recommendations: improving inclusion and trust in cancer early detection research.",
"datePublished": "2023-09-09",
"url": "https://questionsmedicales.fr/article/37689805",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41416-023-02414-8"
}
},
{
"@type": "ScholarlyArticle",
"name": "Evaluation of cell-free DNA approaches for multi-cancer early detection.",
"datePublished": "2022-11-17",
"url": "https://questionsmedicales.fr/article/36400018",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ccell.2022.10.022"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Facteurs biologiques",
"item": "https://questionsmedicales.fr/mesh/D001685"
},
{
"@type": "ListItem",
"position": 3,
"name": "Antigènes",
"item": "https://questionsmedicales.fr/mesh/D000941"
},
{
"@type": "ListItem",
"position": 4,
"name": "Antigènes de surface",
"item": "https://questionsmedicales.fr/mesh/D000954"
},
{
"@type": "ListItem",
"position": 5,
"name": "Molécules d'adhérence cellulaire",
"item": "https://questionsmedicales.fr/mesh/D015815"
},
{
"@type": "ListItem",
"position": 6,
"name": "Lectine-2 de type Ig liant l'acide sialique",
"item": "https://questionsmedicales.fr/mesh/D051918"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Lectine-2 de type Ig liant l'acide sialique - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Lectine-2 de type Ig liant l'acide sialique",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-07",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Lectine-2 de type Ig liant l'acide sialique",
"description": "Comment diagnostiquer une dysfonction de Siglec-2 ?\nQuels tests sont utilisés pour évaluer Siglec-2 ?\nY a-t-il des biomarqueurs associés à Siglec-2 ?\nQuels symptômes peuvent indiquer un problème avec Siglec-2 ?\nComment évaluer l'expression de Siglec-2 ?",
"url": "https://questionsmedicales.fr/mesh/D051918?mesh_terms=Early+Detection+of+Cancer&page=5#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Lectine-2 de type Ig liant l'acide sialique",
"description": "Quels symptômes sont liés à une altération de Siglec-2 ?\nLa fatigue est-elle un symptôme associé à Siglec-2 ?\nDes douleurs articulaires peuvent-elles être liées à Siglec-2 ?\nLes allergies sont-elles influencées par Siglec-2 ?\nY a-t-il des signes cutanés associés à Siglec-2 ?",
"url": "https://questionsmedicales.fr/mesh/D051918?mesh_terms=Early+Detection+of+Cancer&page=5#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Lectine-2 de type Ig liant l'acide sialique",
"description": "Comment prévenir les dysfonctionnements de Siglec-2 ?\nL'alimentation influence-t-elle Siglec-2 ?\nLe stress affecte-t-il Siglec-2 ?\nLes vaccinations aident-elles Siglec-2 ?\nY a-t-il des exercices bénéfiques pour Siglec-2 ?",
"url": "https://questionsmedicales.fr/mesh/D051918?mesh_terms=Early+Detection+of+Cancer&page=5#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Lectine-2 de type Ig liant l'acide sialique",
"description": "Quels traitements ciblent Siglec-2 ?\nLes anti-inflammatoires aident-ils avec Siglec-2 ?\nY a-t-il des traitements expérimentaux pour Siglec-2 ?\nComment la thérapie génique peut-elle aider Siglec-2 ?\nLes probiotiques peuvent-ils influencer Siglec-2 ?",
"url": "https://questionsmedicales.fr/mesh/D051918?mesh_terms=Early+Detection+of+Cancer&page=5#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Lectine-2 de type Ig liant l'acide sialique",
"description": "Quelles complications peuvent survenir avec Siglec-2 ?\nSiglec-2 est-il lié à des cancers ?\nLes maladies cardiovasculaires sont-elles liées à Siglec-2 ?\nY a-t-il des risques neurologiques associés à Siglec-2 ?\nComment les complications de Siglec-2 affectent-elles la qualité de vie ?",
"url": "https://questionsmedicales.fr/mesh/D051918?mesh_terms=Early+Detection+of+Cancer&page=5#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Lectine-2 de type Ig liant l'acide sialique",
"description": "Quels facteurs de risque influencent Siglec-2 ?\nLe tabagisme affecte-t-il Siglec-2 ?\nL'obésité est-elle un facteur de risque pour Siglec-2 ?\nLe diabète influence-t-il Siglec-2 ?\nLe manque de sommeil affecte-t-il Siglec-2 ?",
"url": "https://questionsmedicales.fr/mesh/D051918?mesh_terms=Early+Detection+of+Cancer&page=5#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une dysfonction de Siglec-2 ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests sanguins et des analyses de cellules immunitaires peuvent être effectués."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer Siglec-2 ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'immunohistochimie et les tests de liaison des lectines sont courants."
}
},
{
"@type": "Question",
"name": "Y a-t-il des biomarqueurs associés à Siglec-2 ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des niveaux anormaux de Siglec-2 peuvent servir de biomarqueurs dans certaines maladies."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer un problème avec Siglec-2 ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des infections récurrentes ou une inflammation excessive peuvent être des signes."
}
},
{
"@type": "Question",
"name": "Comment évaluer l'expression de Siglec-2 ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'analyse par cytométrie en flux peut quantifier l'expression de Siglec-2."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés à une altération de Siglec-2 ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des infections fréquentes et des réactions inflammatoires."
}
},
{
"@type": "Question",
"name": "La fatigue est-elle un symptôme associé à Siglec-2 ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la fatigue peut survenir en raison d'une réponse immunitaire altérée."
}
},
{
"@type": "Question",
"name": "Des douleurs articulaires peuvent-elles être liées à Siglec-2 ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une inflammation excessive due à Siglec-2 peut provoquer des douleurs articulaires."
}
},
{
"@type": "Question",
"name": "Les allergies sont-elles influencées par Siglec-2 ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, Siglec-2 peut moduler les réponses allergiques et inflammatoires."
}
},
{
"@type": "Question",
"name": "Y a-t-il des signes cutanés associés à Siglec-2 ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des éruptions cutanées peuvent apparaître en raison d'une inflammation liée à Siglec-2."
}
},
{
"@type": "Question",
"name": "Comment prévenir les dysfonctionnements de Siglec-2 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Maintenir un mode de vie sain et une bonne hygiène peut aider à prévenir les dysfonctionnements."
}
},
{
"@type": "Question",
"name": "L'alimentation influence-t-elle Siglec-2 ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation riche en nutriments peut soutenir la fonction de Siglec-2."
}
},
{
"@type": "Question",
"name": "Le stress affecte-t-il Siglec-2 ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut altérer la fonction immunitaire, y compris celle de Siglec-2."
}
},
{
"@type": "Question",
"name": "Les vaccinations aident-elles Siglec-2 ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les vaccinations peuvent renforcer la réponse immunitaire associée à Siglec-2."
}
},
{
"@type": "Question",
"name": "Y a-t-il des exercices bénéfiques pour Siglec-2 ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exercice régulier peut améliorer la fonction immunitaire et celle de Siglec-2."
}
},
{
"@type": "Question",
"name": "Quels traitements ciblent Siglec-2 ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des thérapies biologiques et des anticorps monoclonaux peuvent cibler Siglec-2."
}
},
{
"@type": "Question",
"name": "Les anti-inflammatoires aident-ils avec Siglec-2 ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les anti-inflammatoires peuvent réduire l'inflammation associée à Siglec-2."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements expérimentaux pour Siglec-2 ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des essais cliniques évaluent des traitements ciblant Siglec-2 pour diverses maladies."
}
},
{
"@type": "Question",
"name": "Comment la thérapie génique peut-elle aider Siglec-2 ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "La thérapie génique pourrait corriger les dysfonctionnements liés à Siglec-2."
}
},
{
"@type": "Question",
"name": "Les probiotiques peuvent-ils influencer Siglec-2 ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains probiotiques peuvent moduler l'expression de Siglec-2 et l'immunité."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec Siglec-2 ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des infections graves et des maladies auto-immunes peuvent être des complications."
}
},
{
"@type": "Question",
"name": "Siglec-2 est-il lié à des cancers ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des altérations de Siglec-2 peuvent être associées à certains types de cancers."
}
},
{
"@type": "Question",
"name": "Les maladies cardiovasculaires sont-elles liées à Siglec-2 ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une inflammation chronique liée à Siglec-2 peut augmenter le risque cardiovasculaire."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques neurologiques associés à Siglec-2 ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des dysfonctionnements de Siglec-2 peuvent être impliqués dans des maladies neurologiques."
}
},
{
"@type": "Question",
"name": "Comment les complications de Siglec-2 affectent-elles la qualité de vie ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications peuvent entraîner des limitations physiques et des problèmes de santé mentale."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque influencent Siglec-2 ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'âge, les maladies chroniques et le mode de vie peuvent influencer la fonction de Siglec-2."
}
},
{
"@type": "Question",
"name": "Le tabagisme affecte-t-il Siglec-2 ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme peut altérer la fonction immunitaire, y compris celle de Siglec-2."
}
},
{
"@type": "Question",
"name": "L'obésité est-elle un facteur de risque pour Siglec-2 ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'obésité peut provoquer une inflammation chronique affectant Siglec-2."
}
},
{
"@type": "Question",
"name": "Le diabète influence-t-il Siglec-2 ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le diabète peut altérer la réponse immunitaire et la fonction de Siglec-2."
}
},
{
"@type": "Question",
"name": "Le manque de sommeil affecte-t-il Siglec-2 ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un sommeil insuffisant peut nuire à la fonction immunitaire, y compris celle de Siglec-2."
}
}
]
}
]
}
Screening programmes utilising blood-based multi-cancer early detection (MCED) tests, which can detect a shared cancer signal from any site in the body with a single, low false-positive rate, could re...
A natural history ('interception') model of cancer was previously used to characterise potential benefits of MCED screening (based on published performance of an MCED test). We built upon this using a...
Estimated late-stage and mortality reductions were robust to a range of assumptions. With the least favourable dwell (sojourn) time and cfDNA status hazard ratio assumptions, we estimated, among 100,0...
Realising the potential benefits of MCED tests could substantially reduce late-stage cancer diagnoses and mortality....
Expert consensus on the potential benefits of early cancer detection does not exist for most cancer types. We convened 10 practicing oncologists using a RAND/UCLA modified Delphi panel to evaluate whi...
Colorectal cancer (CRC) remains the second most common cause of cancer-related mortality worldwide, necessitating advancements in early detection and innovative treatment strategies. MicroRNAs (miRNAs...
Detecting cancer early is essential to improving cancer outcomes. Minoritized groups remain underrepresented in early detection cancer research, which means that findings and interventions are not gen...
In the Circulating Cell-free Genome Atlas (NCT02889978) substudy 1, we evaluate several approaches for a circulating cell-free DNA (cfDNA)-based multi-cancer early detection (MCED) test by defining cl...
Globally, among all women, the most frequently detected and diagnosed and the most lethal type of cancer is breast cancer (BC). In particular, bone is one of the most frequent distant metastases 24in ...
GSE55715, GSE103357, and GSE146661 gene expression profiling data were downloaded from the GEO database. There was 14 breast cancer with bone metastasis samples and 8 breast cancer tissue samples. GEO...
By GO enrichment analysis, 143 DEGs were enriched in the following GO terms: extracellular structure organization, extracellular matrix organization, leukocyte migration class II protein complex, coll...
2 abnormally expressed hub genes could play a pivotal role in the breast cancer with bone metastasis by affecting bone homeostasis imbalance in the bone microenvironment....
Seemingly normal tissues progressively become populated by mutant clones over time. Most of these clones bear mutations in well-known cancer genes but only rarely do they transform into cancer. This p...
We analyzed recent mutational screens of healthy and cancer-free diseased tissues to compare somatic drivers and the causes of somatic variation across tissues. We then reviewed the mechanisms of clon...
The extent of somatic variation is highly variable across tissues and depends on intrinsic features, such as tissue architecture and turnover, as well as the exposure to endogenous and exogenous insul...
Somatic variation and the factors governing homeostasis of normal tissues should be taken into account when devising strategies for cancer prevention and early detection....
The summary presented herein covers recommendations on the early detection of prostate cancer and provides a framework to facilitate clinical decision-making in the implementation of prostate cancer s...
The systematic review utilized to inform this guideline was conducted by an independent methodological consultant. The systematic review was based on searches in Ovid MEDLINE and Embase and Cochrane D...
The Early Detection of Prostate Cancer Panel developed evidence- and consensus-based guideline statements to provide guidance in prostate cancer screening, initial and repeat biopsy, and biopsy techni...
Prostate-specific antigen (PSA)-based prostate cancer screening in combination with shared decision-making (SDM) is recommended. Current data regarding risk from population-based cohorts provide a bas...
Lung cancer is a major global health concern with a low survival rate, often due to late-stage diagnosis. Liquid biopsy offers a non-invasive approach to cancer detection and monitoring, utilizing var...
The present study is a systematic review of the evaluation of screening programs as a strategy for early detection of oral cancer. The aim of this study was to assess whether screening through visual ...